Bristol Myers Squibb and Gilead Sciences recommended for $200 investment due to long-term reliability and growth potential.
Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) are recommended for a $200 investment, as both companies are expected to provide long-term reliability despite recent challenges. Bristol Myers boasts ten medicines generating over $1 billion in sales, with a strong dividend yield of 4.95%. Gilead, a leader in HIV treatments, has seen significant revenue growth and offers a 3.89% dividend yield. Both stocks show promise for growth and income.
September 14, 2024
4 Articles